Molecular prenatal exclusion of familial partial androgen insensitivity (Reifenstein syndrome)

Unite de Biochimie Endocrinienne du Developpement et de la Reproduction, Hopital Lapeyronie, Montpellier, France.

In a large family with Reifenstein syndrome, we previously performed molecular analysis of the androgen receptor gene. Direct sequencing showed a G-A point mutation at position 2818 of exon 7, which was responsible for an arginine-histidine substitution at position 840 of the androgen receptor. In this family, the proband's mother became pregnant and wished to know whether she was carrying an unaffected fetus. Polymerase chain reactions of the sex-determining region of the Y chromosome (the SRY gene) on trophoblastic DNA at week 14 revealed a 46,XY genotype. Sequencing analysis showed the canonical sequence (CGT, encoding an Arg residue), suggesting that the fetus was not affected. The expectation of normal male sexual development was confirmed by detection of normal male external genitalia through ultrasonography at week 24. These data confirm that sequence analysis of the androgen receptor gene on trophoblastic DNA is the most reliable method for prenatally diagnosing or excluding androgen insensitivity syndrome in high-risk families.

This article has been cited by other articles:

				M. Behr, D. B. Ramsden, and U. Loos Deoxyribonucleic Acid Binding and Transcriptional Silencing by a Truncated c-erbA{beta}1 Thyroid Hormone Receptor Identified in a Severely Retarded Patient with Resistance to Thyroid Hormone J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1081 - 1087. [Abstract] [Full Text] [PDF]